152 results
424B5
TPST
Tempest Therapeutics Inc
20 Jun 24
Prospectus supplement for primary offering
8:32am
for the foreseeable future. If we fail to obtain additional funding to conduct our planned research and development efforts, we could be forced to delay … ; (ii) research and development of other product candidates; and (iii) working capital. See “Use of Proceeds” on page S-14 of this prospectus
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
9 May 24
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
4:25pm
to $7.6 million and $0.55, respectively, for the same period in 2023.
Research and development expenses for the quarter were $4.3 million compared to $4.7 … Statements of Operations
(in thousands, except per share amounts)
Three months ended
March 31, 2024
March 31, 2023
Expenses:
Research and development
8-K
EX-99.1
zqyva6pnlalj
19 Mar 24
Tempest Reports Year End 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
j8mrws 0g
8 Nov 23
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.1
xw2uog57o8oj 2aluv
10 Aug 23
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
4:27pm
8-K
EX-99.1
fsv 5tylm9ofs2hmj
10 May 23
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
30uqinjzncx
8 Nov 22
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
8:55am
8-K
EX-99.1
kz8q 14a1s19
15 Aug 22
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
8:05am
424B3
eevuh6a1qvajvcqtzbaa
27 May 22
Prospectus supplement
9:01am